Paragon Biosciences LLC — 2023 Investments

1 investments dated 2023 · listed companies and verified rows first · show all

Evozyneevozyne.com inSep 2023 · $81M✓ verified

Evozyne designs and builds engineered protein therapeutics using an AI-native platform, focusing on treatments for immune-mediated diseases.

AI & Machine LearningBiotechDeep TechHealthtechChicago, US

Aris Theologis(Executive Officer, Director)inDarien Parhad(Executive Officer)Patrick J. Morris(Executive Officer, Director)Marc Yoskowitz(CEO)inRama Ranganathan(Executive Officer, Director)

BoardJeffrey S. Aronin(Director)

Co-investorsOrbiMed Fidelity Investments NVentures NVIDIA Valor Equity Partners

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.